Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Semi-annual Business Results
August 9, 2004
- 1st Qtr Business Results
August 9, 2004
- Annual Business Results
August 9, 2004
- DIAGNOSTIC NEWS IN BRIEF
August 9, 2004
- 1st Qtr Business Results
August 9, 2004
- BULLETIN
August 9, 2004
- BUSINESS NEWS IN BRIEF
August 9, 2004
- 1st Qtr Business Results
August 9, 2004
- FPMAJ to Introduce New Distribution Codes by July 2005
August 9, 2004
- Mitsui & Co to Aggressively Enter into Pharma Business
August 9, 2004
- Iryo Proverbs Reveal Japanese Spirit (21)
August 9, 2004
- MONITOR
August 9, 2004
- Kuraya Sanseido to Put Increased Emphasis on Healthcare-related Business
August 9, 2004
- WORLD NEWS IN BRIEF
August 9, 2004
- Mr Yoshii of Tsumura Sees Bright Future for Kampo Medicine
August 9, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 9, 2004
- Kowa Expects Sales of Livalo to Reach \4.5 Bil. in 1st Year
August 9, 2004
- 1st Qtr Business Results
August 2, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
August 2, 2004
- OTC NEWS IN BRIEF
August 2, 2004
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…